{"id":81445,"date":"2026-11-13T11:07:24","date_gmt":"2026-11-13T11:07:24","guid":{"rendered":"https:\/\/www.europesays.com\/conflicts\/81445\/"},"modified":"2026-11-13T11:07:24","modified_gmt":"2026-11-13T11:07:24","slug":"oura-acquisition-of-startup-raises-conflict-of-interest-questions-for-eli-lilly","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/conflicts\/81445\/","title":{"rendered":"Oura acquisition of startup raises conflict-of-interest questions for Eli Lilly"},"content":{"rendered":"<p class=\"author-bio\">Elaine\u2019s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes <a href=\"https:\/\/www.statnews.com\/signup\/readout\/\" rel=\"nofollow noopener\" target=\"_blank\">The Readout newsletter<\/a>, and co-hosts STAT\u2019s weekly biotech podcast, <a href=\"https:\/\/www.statnews.com\/category\/readout-loud\/\" rel=\"nofollow noopener\" target=\"_blank\">The Readout Loud<\/a>. You can reach Elaine on Signal at elaineywchen.70.<\/p>\n<p class=\"wp-block-paragraph\">Pharma companies that make GLP-1 drugs have increasingly promoted telehealth companies that prescribe the popular treatments. With a new deal announced this week, one of those relationships is expected to grow more complicated.<\/p>\n<p class=\"wp-block-paragraph\">Eli Lilly has been featuring a telehealth company called Counsel Health on <a href=\"https:\/\/www.lilly.com\/lillydirect\" target=\"_blank\" rel=\"noopener nofollow\">a list of providers<\/a> for patients seeking a GLP-1 prescription.<\/p>\n<p class=\"wp-block-paragraph\">On Tuesday, Counsel said it <a href=\"https:\/\/www.statnews.com\/2026\/11\/10\/oura-acquires-counsel-health-big-bet-ai-care\/\" rel=\"nofollow noopener\" target=\"_blank\">would be acquired by the smart ring maker Oura<\/a>, allowing Counsel clinicians access to the data gathered through the ring so they can help customers understand the data and then diagnose or treat any conditions.<\/p>\n<p class=\"restricted-text\">STAT+ Exclusive Story<\/p>\n<p class=\"restricted-login\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t<img decoding=\"async\" class=\"restricted-content-breaker-bg\" src=\"https:\/\/www.europesays.com\/conflicts\/wp-content\/uploads\/2026\/09\/stat-plus-breaker-bg.png\" alt=\"STAT+\"\/><\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n\t\t\t\t\t\t<img decoding=\"async\" class=\"stat-plus-logo\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\" alt=\"STAT+\"\/><br \/>\n\t\t\t\t\t<\/a><\/p>\n<p>\t\t\t\tThis article is exclusive to STAT+ subscribers<br \/>\n\t\t\t\tUnlock this article \u2014 plus daily coverage and analysis of the pharma industry \u2014 by subscribing to STAT+.<\/p>\n<p class=\"restricted-content-breaker-wrapper-cta mobile\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta mobile\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t\t\t\tIndividual plans<\/p>\n<p>\t\t\t\t\t\tGroup plans<\/p>\n<p>\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button view-all\" data-stat-paywall-cta=\"breaker view all plans\" aria-label=\"View All Plans\" rel=\"nofollow noopener\" target=\"_blank\">View All Plans<\/a><\/p>\n<p class=\"restricted-content-text\">\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button restricted-button\" data-stat-paywall-cta=\"breaker subscribe cta 1\" rel=\"nofollow noopener\" target=\"_blank\">Subscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Elaine\u2019s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected&hellip;\n","protected":false},"author":2,"featured_media":81446,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[21,50,40979,40980,20,4379,39843,40981],"class_list":["post-81445","post","type-post","status-publish","format-standard","has-post-thumbnail","category-news","tag-conflict","tag-conflict-news","tag-eli-lilly","tag-health-tech","tag-news","tag-pharmaceuticals","tag-stat","tag-telehealth"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@conflicts\/117608818269274470","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/conflicts\/wp-json\/wp\/v2\/posts\/81445","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/conflicts\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/conflicts\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/conflicts\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/conflicts\/wp-json\/wp\/v2\/comments?post=81445"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/conflicts\/wp-json\/wp\/v2\/posts\/81445\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/conflicts\/wp-json\/wp\/v2\/media\/81446"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/conflicts\/wp-json\/wp\/v2\/media?parent=81445"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/conflicts\/wp-json\/wp\/v2\/categories?post=81445"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/conflicts\/wp-json\/wp\/v2\/tags?post=81445"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}